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ABSTRACT 
Exposure of animals to Perfluorooctanoic acid (PFOA), a surfactant used in emulsion 
polymerization processes causes early pregnancy loss, delayed growth and development 
of fetuses. The mechanisms of action are largely unknown. We studied the effect of 
PFOA on implantation using an in vitro spheroid-endometrial cell co-culture model. 
PFOA (10-100 µM) significantly reduced Jeg-3 spheroid attachment on RL95-2 
endometrial cells. PFOA also suppressed -catenin expression in Jeg-3 cells. The Wnt 
agonist Wnt3a stimulated -catenin expression in Jeg-3 cells and reversed the PFOA 
suppression of the spheroid attachment. The putative PFOA receptors (PPAR,  ) 
present in both cell lines were not affected by PFOA (0.01–100 µM). The PPAR 
antagonist MK886 restored the -catenin and E-cadherin expression levels in Jeg-3 cells 
and reversed the suppression of the spheroid attachment caused by PFOA. Taken together, 
PFOA suppresses spheroid attachment through PPAR and Wnt signaling pathways via 
down-regulation of -catenin and E-cadherin expression.  
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Introduction 
Many natural or man-made chemicals can interfere with the endocrine system 
leading to adverse health effects in both laboratory animals and wildlife species [1]. For 
example, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can disrupt the morphogenesis of 
rat pre-implantation embryos [2], reducing the numbers of implanted embryos and 
live-born pups [3]. 
Perfluorooctanoic acid (PFOA), a known endocrine disruptor, has been used as a 
surfactant in emulsion polymerization processes of fluoropolymers for over 50 years. 
This chemical is present in industrial waste, and has been detected in stain resistant 
carpets, carpet cleaning liquids, water, food, microwave popcorn bags, and house dust [4]. 
Moreover, PFOA is persistent in the environment and has been shown to be toxic to 
laboratory animals and wildlife [5]. Notably, concentrations of PFOA as high as 3.7 ppm 
have been found in house dust [6]. PFOA can enter the human body by inhalation and 
ingestion. It binds to proteins in the blood serum and accumulates in various organs 
including the spleen and liver [7]. PFOA has been detected in the serum of 
fluorochemical production workers (691 ng/mL; range, 72-5100 ng/mL), and its half-life 
in blood is 3.8 years [8]. In various animal studies, PFOA was found to be associated 
with infertility, birth defects and increased cancer risk [4]. However, direct evidence of 
how PFOA affects the fertility of animals is lacking. Several acute oral toxicity studies in 
animals indicate that PFOA causes hepatomegaly and hepatic peroxisome proliferation 
[9]. Moreover, PFOA exposure increases the risk of liver, testicular and pancreatic 
tumors, and causes hormonal disruption and immunotoxicity [4]. Perfluorododecanoic 
acid, a member of the perfluorinated family of compounds, decreased serum testosterone 
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levels but increased estradiol levels in adult rats [10]. PFOA modulated serum hormonal 
effects in rodents causing Leydig cell hyperplasia and adenomas [5], and decreased the 
expression levels of genes involved in steroidogenesis leading to a reduced serum 
testosterone level [10]. 
 PFOA binds to the peroxisome proliferator-activated receptors (PPAR,  and ) 
with varying affinities modulating the downstream biological processes [11] including 
cellular inflammation, reproduction, lipid homeostasis and wound healing [12]. A recent 
study demonstrated that PPAR interacted with the canonical Wnt signaling pathway in 
human cholangiocarcinoma cells [13]. Increasing evidence suggests that the Wnt 
signaling pathway plays very important roles in embryonic development, cell 
differentiation and implantation [14, 15]. Activation of Wnt signaling is mediated by 
binding of Wnt ligands (e.g. Wnt3a) to its receptor allowing accumulation of -catenin 
for gene transcription and downstream biological processes. How PFOA binds to PPAR 
and affects the activation of the Wnt signaling pathway for embryo implantation remains 
largely unknown. We investigated the mechanism of action of PFOA on implantation by 
studying spheroid attachment using human trophoblastic spheroids (Jeg-3) and 
endometrial epithelial cells (RL95-2) in a co-culture assay. Because the use of human 
embryos and primary endometrial epithelial cells is limited, this in vitro co-culture model 
can mimic the initial embryo (spheroids) attachment process using well-established 
human cell lines. We used PPAR inhibitors to further elucidate the mechanism of 
PFOA/PPARs regulation of the canonical Wnt signaling molecules in both Jeg-3 and 
RL95-2 cells during the spheroid attachment process. 
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1. Materials and methods 
2.1 Cell culture 
Human choriocarcinoma Jeg-3 (HTB-36, ATCC) and endometrial adenocarcinoma 
RL95-2 (CRL-1671, ATCC) cells were both cultured at 37oC in a humid atmosphere in 
5% CO2. Cells were maintained in DMEM/F12 (Sigma, MO, USA), supplemented with 
10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA), 2 mM L-glutamine and 
penicillin/streptomycin (100 U/ml and 0.1 mg/ml) (Gibco, NY, USA). For each 
experiment, 1 x 105 cells were suspended in the cell culture medium and seeded in 
12-well tissue culture plates (Iwaki, Japan). PFOA (96% purity, Sigma) was dissolved in 
dimethyl sulfoxide (DMSO). The Jeg-3 and RL95-2 cells were then cultured in 
PFOA-containing culture medium for 24 hrs prior to either Western blotting or spheroid 
generation for co-culture study. PFOA concentrations ranging from 0.01 to 100 µM were 
prepared in DMSO (0.1% final concentration) and 0.1% DMSO was used as the negative 
control. All treatments were repeated in duplicate at least five times. 
 
2.2 Protein extraction and Western blotting 
Total protein from cell lysates was dissolved in RIPA solution (1X PBS, 1% Nonidet 
P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors. The proteins 
were separated by SDS-PAGE and transferred onto a PVDF membrane. For Western 
blotting, antibodies specific for PPARα (sc-1985, Santa Cruz, CA, USA), PPAR 
(sc-7197, Santa Cruz), PPARγ (sc-7273, Santa Cruz), -catenin (1:2500) (BD Bioscience, 
CA, USA) and E-cadherin (1:1000) (Abcam, Cambridge, MA, USA) were used. 
Anti-rabbit, anti-mouse (1:5000) (GE Healthcare, Pittsburgh, PA) or anti-goat antibodies 
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(1:5000) (Santa Cruz) were used as the horseradish peroxidase-conjugated secondary 
antibody. The membranes were visualized by enhanced chemiluminescence (Santa Cruz). 
To normalize the protein loading, the membranes were stripped and re-blotted with 
anti--actin antibody (Sigma). 
 
2.3 Cell proliferation and cell viability assay 
For the cell proliferation assay, 3 × 103 cells were seeded per well in triplicate in 
96-well plates. Jeg-3 or RL95-2 cells were cultured for 3 days with different 
concentrations of PFOA. CyQUANT® Cell Proliferation Assay kit was used to 
determine the cell number by measuring its DNA content on day 1, 2 and 3. Briefly, 
CyQUANT® NF dye reagent was mixed with the 1X Hank’s balanced salt solution 
(HBSS), and 100 μL of this 1X dye solution was added into each microplate well for 
DNA binding. After incubating for 1 hr at 37°C, the fluorescent signal was measured at 
535 nm. 
For the cell viability assay, 2 × 105 cells were seeded per well in duplicate in 
six-well plates. Jeg-3 or RL95-2 cells were cultured for 24 hrs with different 
concentrations of the treatments. The treated cells were trypsinized and the cell 
suspension was centrifuged for 5 mins at 100 g. The cell pellet was resuspended in 500 µl 
of PBS containing 0.4% trypan blue. The unstained (viable) and the stained (nonviable) 
cells were counted using a hemacytometer. The percentage of viable cells was calculated 
from the total number of cells.  
 
2.4 Spheroid attachment assay 
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The Jeg-3 and RL95-2 cells were cultured at 37°C in a humid atmosphere in 5% 
CO2 as above. Adhesion of the choriocarcinoma Jeg-3 spheroids on the endometrial 
RL95-2 cells was quantified using an adhesion assay as previously described [16]. In the 
co-culture assay, trophoblastic Jeg-3 and endometrial epithelial RL95-2 cells were treated 
with PFOA (1-100 µM) with or without inhibitors of PPARα (10M) (MK886, Biomol 
Res Lab, PA, USA), PPARβ (10M) (GSK0660, Sigma) and PPARγ (1M) (GW9662, 
Sigma), or 50% Wnt3a conditioned medium (Wnt3a-CM, 1:1) for 24 hrs before 
generation of spheroids and co-culture, respectively. The control was the cell 
differentiation reagent, methotrexate (MTX, 5 μM) (Hohn et al., 2000) and the negative 
control was DMSO alone. Spheroids were generated by rotating the trypsinized Jeg-3 
cells at 4 g for 24 hrs without PFOA or PPAR inhibitors. Spheroids with sizes ranging 
from 60 to 200 μm were selected and transferred onto the confluent monolayer of 
endometrial cells under a dissection microscope, and co-cultured without PFOA or PPAR 
inhibitors for 1 hr at 37°C in a humidified atmosphere in 5% CO2. Non-adherent 
spheroids were removed by centrifugation in the medium at 10 g for 10 mins. Attached 
spheroids were counted under a microscope and the attachment rate was expressed as a 
percentage of the total number of spheroids transferred (% adhesion). Images of the 
cultures were taken using a Nikon Eclipse TE300 inverted microscope (Nikon, Tokyo, 
Japan). 
 
2.5 Wnt signaling activation 
Wnt3a conditioned medium (Wnt3a-CM) was obtained from the culture of mouse L 
cells stably secreting the Wnt3a protein. Briefly, mouse fibroblast L cells over-expressing 
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Wnt3a (CRL-2647, ATCC) were cultured in DMEM medium supplemented with 10% 
FBS, L-glutamine and penicillin/streptomycin. The conditioned medium was collected 
after 48 hrs of confluent culture and the expression of Wnt3a protein was confirmed by 
Western blotting using a specific anti-Wnt3a antibody. The conditioned medium obtained 
from normal mouse fibroblast L cells was used as the negative control for the spheroid 
attachment assay. All conditioned media were filter-sterilized and stored at -20oC until 
used. 
 
2.6 Statistical analysis 
 All results were calculated as the mean ± standard error of mean (SEM) from at least 
three independent experiments. All the data were analyzed using the SigmaPlot statistical 
software (SigmaPlot 11.0; Jandel Scientific, San Rafael, California, USA). The 
Mann-Whitney U test was used when the data was not normally distributed. A p-value of 
less than 0.05 was considered to be statistically significant.  
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2. Results 
3.1 Effect of PFOA on the expression of PPARs in trophoblastic and endometrial cell 
lines 
 The three PPAR isotypes (PPARα, PPARβ and PPARγ) have similar molecular 
weights but have unique structures associated with the subtype specificity. PFOA 
(0.01-100 µM) did not significantly change the expression of PPARα, PPARβ and PPARγ 
in both the Jeg-3 and RL95-2 cells as determined by Western blotting (Figure 1A & B). 
 
3.2 PFOA suppressed spheroid attachment onto endometrial cells 
 A spheroid-endometrial cell co-culture assay was used to study whether PFOA 
modulated the attachment of spheroids (blastocyst surrogate) in vitro. The number of 
attached spheroids was determined after 1 hr of co-culture. A significant decrease in the 
spheroid attachment rate was observed only when the Jeg-3 cells were treated with PFOA 
(100 M) (Figure 2). When both Jeg-3 and RL95-2 cells were treated with PFOA (10 and 
100 µM), the spheroid attachment was significantly decreased (p<0.05 and p<0.01, 
respectively) (Figure 2). The average viability and proliferation rate of PFOA (1-100M) 
treated cells were comparable to the controls as determined by Trypan blue and the 
CyQUANT cell proliferation assay, respectively (data not shown). MTX (5 M) strongly 
suppressed spheroid attachment (p<0.05) and was used as the treatment control. 
 
3.3 Wnt3a reversed the suppressive effect of PFOA on -catenin expression and 
spheroid attachment in the co-culture model 
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The effect of PFOA treatment on β-catenin and E-cadherin expressions was studied to 
determine whether PFOA suppresses spheroid attachment through down-regulation of the 
Wnt signaling pathway. Treatment with PFOA (10 and 100 µM) for 24 hrs strongly 
suppressed the expression of β-catenin in the Jeg-3 cells but not in the RL95-2 cells (Figure 
3A & B). Treatment with PFOA (100 µM) also significantly decreased the expression of 
E-cadherin in the Jeg-3 cells. No observable change in the expression of β-actin was 
detected with PFOA treatments. 
Wnt3a conditioned medium (Wnt3a-CM) was used to activate the Wnt signaling 
pathway in the Jeg-3 and RL95-2 cells. Wnt3a-CM (1:1, v/v) alone had no significant 
effect on cell viability and proliferation (data not shown). PFOA (10 - 100 µM) strongly 
suppressed β-catenin expression in only the Jeg-3 cells and this suppressive effect was 
reversed in Wnt3a-CM (Figure 4A). The expression of β-actin protein remained 
unchanged in Wnt3a-CM and was used as the loading control. Wnt3a-CM treatment (1:1, 
v/v) reversed the suppressive effect of PFOA (10 and 100 M) on the spheroid attachment 
compared to the Wnt3a-CM control (Figure 4B). However, Wnt3a-CM itself had a 
stimulatory effect on -catenin expression in Jeg-3 cells and on spheroid attachment in 
vitro. The MTX (5 µM) control strongly suppressed spheroid attachment (p<0.05). 
 
3.4 Effects of PPAR antagonists on PFOA suppression of the spheroid attachment 
We used PPARα, PPARβ and PPARγ antagonists (MK886, GSK0660 and GW9662, 
respectively) to study the role of PPARs in the PFOA suppression of the -catenin 
expression and spheroid attachment. The concentration of the inhibitors used in this study 
did not affect the viability and proliferation of the treated cells (data not shown). Western 
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blot analysis showed that PFOA strongly suppressed -catenin and E-cadherin 
expressions in Jeg-3 cells, and addition of Wnt3a reversed these suppressive effects. 
Importantly, treatment of Jeg-3 cells with MK886 (10 µM), but not GSK0660 (10 µM) or 
GW9662 (1 µM), reversed the suppressive effects of PFOA on the expression of 
-catenin and E-cadherin (Figure 5A). However, PFOA did not affect the expression of 
-catenin and E-cadherin in the RL95-2 cells. We found that the PPAR inhibitor MK886 
(10 µM) reversed the PFOA (100 µM) suppression of the spheroid attachment (Figure 
5B), whereas the PPARγ inhibitor GW9662 (1 µM) partially reversed the suppressive 
effects of PFOA when compared with PFOA treatment group. No significant change was 
observed when the cells were treated with the PPARβ inhibitor GSK0660 (10 µM). 
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3. Discussion 
 The mechanism of PFOA suppression of trophoblastic spheroid attachment seems 
to be mainly via the down-regulation of the Wnt signaling pathway in trophoblastic cells. 
The PFOA suppression of spheroid attachment was reversed by Wnt3a and the PPARα 
inhibitor MK886 suggesting the involvement of cross-talk between the Wnt signaling and 
PPAR pathways in modulating this suppressive effect. 
PFOA can activate PPAR in an in vitro model system. Activation of the PPARs 
leads to transcription of target genes and modulation of various biological processes 
including energy homeostasis, lipid metabolism, cell differentiation [17] and pregnancy 
[18]. In the present study, both the RL95-2 and the Jeg-3 cells expressed PPARα, PPARβ 
and PPARγ. Although PFOA (0.01-100 µM) did not affect the expression of PPARs and 
cell viability in Jeg-3 and RL95-2 cells (data not shown), other studies report that PFOA at 
higher concentrations (50-500M) can induce cytotoxic effects and change cell cycle 
profiles in cells in vitro [19, 20]. 
The spheroids-endometrial cells co-culture assay was used to study the attachment 
process in vitro [21]. Three different treatment groups (Jeg-3 cells, RL95-2 cells, and both 
cell lines) were used to study the effect of PFOA on the two cell lines. When both cells 
were treated with PFOA (10 and 100 M), the spheroid attachment rates decreased 
significantly. A similar suppressive effect was observed when Jeg-3 cells were treated with 
PFOA (100 µM), suggesting the suppressive effect of PFOA is mainly through 
trophoblastic cells. 
The canonical Wnt signaling pathway regulates embryo implantation and early 
embryonic development [15, 22]. PFOA strongly suppresses -catenin and E-cadherin 
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expression in the Jeg-3 cells, but how these changes affect spheroid attachment remains 
largely unknown. The expression of endometrial E-cadherin and -catenin are higher in 
healthy fertile women, and impaired down-regulation of endometrial E-cadherin and 
-catenin expression during the window of implantation is associated with infertility in 
patients with endometriosis [23]. In contrast, up-regulation of -catenin in the apical 
membrane of epithelial cells at the implantation sites was observed in mice [24]. In line 
with these observations, we found that Wnt3a-CM up-regulated -catenin expression in 
Jeg-3 cells and stimulated spheroid attachment. Similarly, addition of the Wnt agonist 
Wnt3a restored -catenin expression in Jeg-3 cells and reversed the suppressed spheroid 
attachment caused by PFOA. These observations relating to spheroids attachment are in 
agreement with our previous findings on trophoblastic (BeWo) and endometrial (RL95-2) 
cells treated with another endocrine disruptor, TCDD [25], or oviductal epithelial 
(OE-E6/E7) cells treated with a Wnt antagonist, Olfm [26]. 
To determine whether PFOA interacts with PPARs to affect spheroid attachment, we 
used three PPAR antagonists (MK886, GSK0660 and GW9662). MK886 inhibits PPARα 
through a non-competitive mechanism that prevents conformational change during the 
active-complex formation [27]. GSK0660 is a potent PPARβ/δ antagonist [28] and 
GW9662 covalently modifies the cysteine residue at the binding site of PPARγ [29]. The 
concentrations of the PPARs antagonists used were specific for inhibiting the different 
PPAR receptors [28, 30, 31]. However, the effect of the specific antagonist on 
development and pregnancy outcome in animals remains largely unknown. Our findings 
showed that MK886 reversed the PFOA-induced suppression of the spheroid attachment, 
but GSK0660 had no reversing effect, and GW9662 could only partially reverse the effects 
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of PFOA (100 µM) when compared with PFOA treated group. This suggests that PFOA 
exerts its effect mainly through the PPARα pathway. Although mice deficient in PPAR 
are not associated with early pregnancy lost, PPAR is required for PFOA-induced 
postnatal lethality [32]. Treatment with a lower concentration of PFOA (10 M) in both the 
Jeg-3 and RL95-2 cells affected spheroid attachment, but PFOA (10 M) with RL95-2 
cells alone had no effect on -catenin expression and spheroid attachment. This suggests 
that PFOA may affect the expression of other molecule(s) that are important for spheroid 
and endometrial cells interaction in vitro. 
Our results show that PFOA suppressed spheroid attachment on endometrial 
epithelial cells, which is mediated by PPAR and suppression of the Wnt signaling 
pathway via down-regulation of β-catenin and E-cadherin expression. Although our 
experimental concentrations were 100-fold higher, the current findings suggest that the 
PFOA serum levels (72-5,100 ng/ml or 0.17-12 M) could potentially have detrimental 
effects on spheroid attachment on endometrial cells in vivo. PFOA may, therefore, disrupt 
cell-cell adhesion important for the initial embryo attachment in vivo. The combined effect 
of PFOA with other endocrine disruptors (e.g. TCDD, BPA) [25] on human body should 
not be underestimated.  
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Figure legend 
 
Figure 1 Effects of PFOA on PPAR expression. (A) The expression of peroxisome 
proliferator-activated receptors (PPAR and  in human choriocarcinoma Jeg-3 and 
endometrial epithelial RL95-2 cells treated with PFOA (0.01 - 100 M) for 24 hrs. PFOA 
(0.01 - 100 µM) treatment did not significantly alter the expression of PPARs proteins in 
Jeg-3 and RL95-2 cells. The expression of -actin was used as the loading control. (B) 
The expressions of PPAR and  were quantified relative to -actin expression in 
Jeg-3 and RL95-2 cells. 
 
Figure 2 Effects of PFOA on Jeg-3 spheroids (blastocyst surrogate) and RL95-2 
(endometrial epithelial cells) cell attachment assay. (Upper panel) PFOA (100 µM) 
treated Jeg-3 cells suppressed spheroid attachment. (Middle panel) PFOA (1 - 100 M) 
treated RL95-2 cells showed no observable changes to the spheroid attachment. (Bottom 
panel) PFOA (10 and 100 M) strongly suppressed Jeg-3 spheroids attachment on 
RL95-2 cells. The numbers in the bar represent the total number of attached spheroids 
over the total number of spheroids added. *p<0.05, **p<0.005 and ***p<0.001 denote 
significant differences from the untreated control (Con). 
 
Figure 3 Effects of PFOA on -catenin and E-cadherin expressions in Jeg-3 and 
RL95-2 cells. (A) Jeg-3 and RL95-2 cells were treated with PFOA (0.01 - 100 µM) for 
24 hrs. The expression of β-catenin and E-cadherin were reduced in Jeg-3 but not in 
RL95-2 cells. No change was observed in -actin expression. (B) The expressions of 
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-catenin and E-cadherin were quantified relative to -actin expression in Jeg-3 and 
RL95-2 cells. *p<0.05 and **p<0.01 denote significant differences from the control.  
 
Figure 4 Wnt3a restored the suppressive effect of PFOA on -catenin expression 
and spheroid attachment. (A) Wnt3a conditioned medium (Wnt3a-CM; 1:1, v/v) 
reversed the suppressive effect of PFOA on β-catenin expression in Jeg-3 cells but not in 
RL95-2 cells. No change was observed in -actin expression. (B) Wnt3a-CM (1:1, v/v) 
nullified the suppressive effect of PFOA on Jeg-3 spheroid attachment onto RL95-2 cells, 
but also stimulated spheroid attachment in the absence of PFOA. *p<0.05, **p<0.005 
and ***p<0.001 denote significant differences from the control. 
 
Figure 5 PPAR antagonists reversed the suppressive effect of PFOA on -catenin 
and E-cadherin expression and spheroid attachment. (A) Western blots of Jeg-3 and 
RL95-2 cells treated with PFOA (100 M), Wnt3a-CM (Wnt3a) and PPAR inhibitors 
(MK886, GSK0660 and GW9662). PFOA suppressed -catenin and E-cadherin 
expression; whereas Wnt3a induced -catenin expression in the Jeg-3 cells. Addition of 
MK886, but not GSK0660 or GW9662, reversed the suppressive effect of PFOA on 
-catenin and E-cadherin expressions in the Jeg-3 cells. No significant change in 
-catenin and E-cadherin expressions was found in RL95-2 cells. -actin was used as the 
loading control. (B) PFOA (100 M) suppressed Jeg-3 spheroid attached on RL95-2 cells. 
The suppressive effect could be nullified by treating the cells with MK886 (10 M) but 
not GSK0660 (10 M). The suppressive effect could be partially nullified by GW9662 (1 
M). MK886, GSK0660 or GW9662 alone had no effect on spheroid attachment. MTX 
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(5 M) strongly suppressed (p<0.001) spheroid attachment and was used as a positive 
control. *p<0.05, **p<0.005 and ***p<0.001 denote significant differences from the 
control. 
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